CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
2.010
+0.020 (1.01%)
At close: Oct 1, 2025, 4:00 PM EDT
2.040
+0.030 (1.49%)
After-hours: Oct 1, 2025, 4:17 PM EDT
CytoMed Therapeutics Revenue
In the year 2024, CytoMed Therapeutics had annual revenue of 503.37K SGD, down -0.86%. CytoMed Therapeutics had revenue of 279.19K in the half year ending December 31, 2024, a decrease of -3.52%.
Revenue (ttm)
503.37K SGD
Revenue Growth
-0.86%
P/S Ratio
-2,813.95
Revenue / Employee
11,706 SGD
Employees
43
Market Cap
23.08M USD
Revenue Chart
* This company reports financials in SGD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 503.37K | -4.36K | -0.86% |
| Dec 31, 2023 | 507.74K | 143.82K | 39.52% |
| Dec 31, 2022 | 363.91K | 250.07K | 219.67% |
| Dec 31, 2021 | 113.84K | 54.37K | 91.43% |
| Dec 31, 2020 | 59.47K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
GDTC News
- 4 weeks ago - Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition - GlobeNewsWire
- 6 weeks ago - CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program - GlobeNewsWire
- 2 months ago - Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - GlobeNewsWire
- 5 months ago - CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates - GlobeNewsWire
- 8 months ago - CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders - GlobeNewsWire
- 9 months ago - Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga
- 1 year ago - Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewsWire
- 1 year ago - CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewsWire